AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (100 mL, 0.2 g/100 mL)
Number of subjects: 24
Study 36900554 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (200 mL)
Number of subjects: 24
Study 36900802 — intervention group
Group type: EXPERIMENTAL
Intervention: Road Cycling (RC)
Number of subjects: 40
Study 36900802 — intervention group
Group type: COMPARATOR
Intervention: Mountain Biking (MTB)
Number of subjects: 40
Study 36900811 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from a physiotherapist (PT) with higher follow-up frequency and aerobic physical fitness tests
Number of subjects: 190
Study 36900811 — intervention group
Group type: COMPARATOR
Intervention: Continued physical activity on prescription at a healthcare center (HCC)
Number of subjects: 190
Study 36900872 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported approach for early screening of frailty risk factors using the SUNFRAIL questionnaire and in-depth scale tests.
Number of subjects: 100
Study 36900872 — intervention group
Group type: EXPERIMENTAL
Intervention: SUNFRAIL questionnaire administered by seven centers.
Number of subjects: 100
Study 36901227 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VeNS
Number of subjects: 66
Study 36901227 — intervention group
Group type: COMPARATOR
Intervention: Sham VeNS
Number of subjects: 66
Study 36901671 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen music intervention
Number of subjects: 82
Study 36901671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study 36902139 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL-2 inhibitors (specific drugs not detailed)
Number of subjects: 0
Study 36902139 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 pathway inhibitors (specific drugs not detailed)
Number of subjects: 0
Study 36902139 — intervention group
Group type: EXPERIMENTAL
Intervention: S63845, S64315, chidamide, arsenic trioxide (ATO)
Number of subjects: 0
Study 36902139 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of the PD-L1 gene
Number of subjects: 0
Study 36902217 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Number of subjects: 0
Study 36902217 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Number of subjects: 0
Study 36902536 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasonography (POCUS) assessment
Number of subjects: 36
Study 36902536 — intervention group
Group type: COMPARATOR
Intervention: Standard care (non-POCUS)
Number of subjects: 36
Study 36902798 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation plus stereotactic radiation to all metastatic sites and radium223
Number of subjects: 38
Study 36902798 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 38
Study 36902798 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging (PSMA or fluciclovine PET)
Number of subjects: 38
Study 36902798 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 38
Study 36902798 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional imaging or tumor board adjudication
Number of subjects: 38
Study 36902861 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for displaced DRFs
Number of subjects: 50
Study 36902861 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for minimally or non-displaced DRFs
Number of subjects: 50
Study 36902861 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for both groups
Number of subjects: 50
Study 36904212 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and micronutrients intervention
Number of subjects: 0
Study 36904212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NSBs)
Number of subjects: 80
Study 36904237 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 80
Study 36904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic Fat sub-study (intrahepatocellular lipid by 1H-MRS)
Number of subjects: 80
Study 36904251 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% of daily energy)
Number of subjects: 0
Study 36904251 — intervention group
Group type: COMPARATOR
Intervention: Control group (walnut-free diet)
Number of subjects: 0
Study 36905131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 48 weeks
Number of subjects: 84
Study 36905131 — intervention group
Group type: COMPARATOR
Intervention: Active control (health education)
Number of subjects: 84
Study 36905161 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (E-Stim) on both gastrocnemius muscles for 1 hour daily for 4 weeks
Number of subjects: 18
Study 36905161 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctional electrical stimulation device (Control group)
Number of subjects: 18
Study 36905177 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilms' tumor 1 expression
Number of subjects: 0
Study 36905177 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mutations
Number of subjects: 0
Study 36905198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 38
Study 36905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Intensity Continuous Training (MICT)
Number of subjects: 38
Study 36905248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10251
Study 36905248 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 10251
Study 36905347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) ranging between 65 mmHg and 120 mmHg during anesthesia and surgery
Number of subjects: 100
Study 36905347 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP lower than 65 mmHg
Number of subjects: 100
Study 36905390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 300
Study 36905390 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary
Number of subjects: 300
Study 36905390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary and vaginal progesterone
Number of subjects: 300
Study 36905419 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial training in virtual reality
Number of subjects: 17
Study 36905419 — intervention group
Group type: COMPARATOR
Intervention: Non-Spatial control training
Number of subjects: 17
Study 36905441 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (measured and transmitted home BP readings)
Number of subjects: 49
Study 36905441 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (face-to-face consultations)
Number of subjects: 49
Study 36905441 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 49
Study 36905458 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet adherence
Number of subjects: 658
Study 36905458 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful plant-based dietary index
Number of subjects: 658
Study 36905458 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based dietary index
Number of subjects: 658
Study 36905458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption (≥0.93 portion/week)
Number of subjects: 658
Study 36905485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 419
Study 36905485 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 419
Study 36905498 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-46000 (subcutaneous LAI antipsychotic agent)
Number of subjects: 63
Study 36905528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab immunogenicity assessed using electrochemiluminescence (ECL) and enzyme-linked immunosorbent (ELISA) assays.
Number of subjects: 1459
Study 36905528 — intervention group
Group type: EXPERIMENTAL
Intervention: Titer-based classification with lower limit of quantitation (LLOQ) as threshold.
Number of subjects: 1459
Study 36905528 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise population pharmacokinetic (popPK) modeling.
Number of subjects: 1459
Study 36905528 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA assay for immunogenicity.
Number of subjects: 1459
Study 36905632 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving practice for older drivers with MCI
Number of subjects: 12
Study 36905632 — intervention group
Group type: COMPARATOR
Intervention: Normal cognition (NC) drivers
Number of subjects: 12
Study 36905719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 10 mg
Number of subjects: 70
Study 36905719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 30 mg
Number of subjects: 70
Study 36905719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen 75 mg
Number of subjects: 70
Study 36905719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36905736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 87
Study 36905771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg on days 0, 14 and 28, then every 28 ± 3 days, n = 77)
Number of subjects: 145
Study 36905771 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (25 mg/day, n = 67)
Number of subjects: 145
Study 36905771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 145
Study 36905771 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 145
Study 36905980 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + ECIG retraining
Number of subjects: 90
Study 36905980 — intervention group
Group type: EXPERIMENTAL
Intervention: CC only retraining
Number of subjects: 90
Study 36905980 — intervention group
Group type: COMPARATOR
Intervention: Sham retraining
Number of subjects: 90
Study 36906081 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide hemostatic powder (PHP) with diluted epinephrine injection and powder application as spray
Number of subjects: 216
Study 36906081 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic treatment (electrical coagulation or hemoclipping after diluted epinephrine injection)
Number of subjects: 216
Study 36906081 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 216
Study 36906262 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported triggers (median number 8, interquartile range 5-10)
Number of subjects: 2793
Study 36906262 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional trigger reported
Number of subjects: 2793
Study 36906262 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger number
Number of subjects: 2793
Study 36906345 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1-BPZE1
Number of subjects: 280
Study 36906345 — intervention group
Group type: COMPARATOR
Intervention: BPZE1-placebo
Number of subjects: 280
Study 36906345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-BPZE1
Number of subjects: 280
Study 36906345 — intervention group
Group type: COMPARATOR
Intervention: Tdap-placebo
Number of subjects: 280
Study 36906440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg) in the posaconazole-HSCT population
Number of subjects: 87
Study 36906440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg) in the fidaxomicin-HSCT population
Number of subjects: 87
Study 36906440 — intervention group
Group type: COMPARATOR
Intervention: Pooled Phase III/Phase I data set
Number of subjects: 87
Study 36906589 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT+) intervention (n=375)
Number of subjects: 750
Study 36906589 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition (n=375)
Number of subjects: 750
Study 36906660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus belimumab
Number of subjects: 36
Study 36906660 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus placebo
Number of subjects: 36
Study 36906664 — intervention group
Group type: EXPERIMENTAL
Intervention: CD46-targeted alpha therapy based on YS5
Number of subjects: 0
Study 36906664 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtubule inhibitor-based antibody drug conjugate
Number of subjects: 0
Study 36906804 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy
Number of subjects: 1420
Study 36906804 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen strategy
Number of subjects: 1420
Study 36906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CYT107 (10 µg/kg)
Number of subjects: 21
Study 36906875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 36906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CYT107
Number of subjects: 21
Study 36906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular CYT107 (previous study)
Number of subjects: 21
Study 36907376 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography cluster of periodic limb movements of sleep (PLMS)
Number of subjects: 29907
Study 36907376 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography cluster of severe desaturations
Number of subjects: 29907
Study 36907376 — intervention group
Group type: COMPARATOR
Intervention: Mild polysomnography cluster
Number of subjects: 29907
Study 36907376 — intervention group
Group type: COMPARATOR
Intervention: Other polysomnography clusters (poor sleep, severe OSA or sleep fragmentation)
Number of subjects: 29907
Study 36907457 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 87
Study 36907457 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 87
Study 36907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 273
Study 36907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 273
Study 36907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 273
Study 36907736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 273
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth pure-tone screening with tympanometry
Number of subjects: 1449
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency mHealth pure-tone screening with tympanometry
Number of subjects: 1449
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE with tympanometry
Number of subjects: 1449
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth pure-tone screening with 6 kHz
Number of subjects: 1449
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE plus tympanometry for children 3 to 6 years
Number of subjects: 1449
Study 36907833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency mHealth pure-tone screening for children 7 years and older
Number of subjects: 1449
Study 36907851 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotic treatment
Number of subjects: 78
Study 36907851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbiota at birth
Number of subjects: 78
Study 36907851 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal meconium communities
Number of subjects: 78
Study 36907899 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Program (BrCaRRP)
Number of subjects: 0
Study 36907899 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36907945 — intervention group
Group type: EXPERIMENTAL
Intervention: M-DEPTH depression care model (including antidepressants and individual Problem Solving Therapy)
Number of subjects: 391
Study 36907945 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 391
Study 36907947 — intervention group
Group type: EXPERIMENTAL
Intervention: Alofanib (350 mg/m2, administered daily intravenously 5 days on, 2 days off)
Number of subjects: 21
Study 36907947 — intervention group
Group type: EXPERIMENTAL
Intervention: Alofanib
Number of subjects: 21
Study 36907985 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) initiated within 48 hours post-AIS
Number of subjects: 509
Study 36907997 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal azithromycin (500 mg oral tablets)
Number of subjects: 50
Study 36907997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no azithromycin)
Number of subjects: 50
Study 36908150 — intervention group
Group type: COMPARATOR
Intervention: 2 mg pitavastatin
Number of subjects: 293
Study 36908150 — intervention group
Group type: COMPARATOR
Intervention: 4 mg pitavastatin
Number of subjects: 293
Study 36908150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg pitavastatin/10 mg ezetimibe (K-924 LD)
Number of subjects: 293
Study 36908150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg pitavastatin/10 mg ezetimibe (K-924 HD)
Number of subjects: 293
Study 36908150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin/ezetimibe fixed-dose combination
Number of subjects: 293
Study 36908150 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin monotherapy
Number of subjects: 293
Study 36908150 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin/ezetimibe fixed-dose combination and pitavastatin monotherapy
Number of subjects: 293
Study 36908150 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 293
Study 36908163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior-CB (Cryoablation)
Number of subjects: 74
Study 36908163 — intervention group
Group type: COMPARATOR
Intervention: Prior-RF (Radiofrequency catheter ablation)
Number of subjects: 74
Study 36908314 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per day
Number of subjects: 279
Study 36908314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 36908422 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD/IVR
Number of subjects: 334
Study 36908422 — intervention group
Group type: EXPERIMENTAL
Intervention: Class/IVR
Number of subjects: 334
Study 36908422 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 334
Study 36908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to routine activities due to anti-Asian racism
Number of subjects: 175
Study 36908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to routine activities
Number of subjects: 175
Study 36908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear for safety due to anti-Asian racism
Number of subjects: 175
Study 36908462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear for safety
Number of subjects: 175
Study 36908503 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 255
Study 36908503 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Number of subjects: 255
Study 36908503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Daclatasvir
Number of subjects: 255
Study 36908503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 36908609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids treatment
Number of subjects: 0
Study 36908609 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-ON group, AQP4-IgG+ON group, MOG-IgG+ON group
Number of subjects: 0
Study 36908614 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 211
Study 36908614 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 211
Study 36908614 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 211
Study 36908619 — intervention group
Group type: EXPERIMENTAL
Intervention: ApTOLL (Toll-like receptor 4 antagonist) administered together with endovascular treatment (EVT)
Number of subjects: 151
Study 36908619 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered together with endovascular treatment (EVT)
Number of subjects: 151
Study 36908633 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Chinese foot massages (TCFM)
Number of subjects: 142
Study 36908633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 36908662 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired coronary flow reserve (CFR)
Number of subjects: 0
Study 36908662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation
Number of subjects: 0
Study 36908766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain, depression, and anxiety medications
Number of subjects: 3246
Study 36908766 — intervention group
Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 3246
Study 36908924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Number of subjects: 200
Study 36908924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 36909004 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Number of subjects: 96
Study 36909004 — intervention group
Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 96
Study 36909004 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 36909343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 6
Study 36909343 — intervention group
Group type: COMPARATOR
Intervention: Placebo shake
Number of subjects: 6
Study 36909590 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx-Hunger
Number of subjects: 640
Study 36909590 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx-Dementia
Number of subjects: 640
Study 36909596 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention (TBRI) Caregiver Training, a trauma-informed intervention program.
Number of subjects: 0